These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 22658652

  • 1. Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
    Yeom SY, Lee SJ, Kim WS, Park C.
    Leuk Res; 2012 Sep; 36(9):1172-8. PubMed ID: 22658652
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J.
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
    Lü S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J.
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P, Xu B, Li J, Lu H.
    FEBS Lett; 2009 Jan 22; 583(2):401-6. PubMed ID: 19111544
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.
    Oncogene; 2009 Jan 15; 28(2):231-42. PubMed ID: 18850009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, Leboeuf C, Janin A, Chen SJ, Zhao WL.
    Ann Hematol; 2011 Jan 15; 90(1):53-8. PubMed ID: 20617436
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.
    Br J Haematol; 2006 Jul 15; 134(2):145-56. PubMed ID: 16846475
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
    Li QF, Yan J, Zhang K, Yang YF, Xiao FJ, Wu CT, Wang H, Wang LS.
    Biochem Biophys Res Commun; 2011 Feb 04; 405(1):31-6. PubMed ID: 21195056
    [Abstract] [Full Text] [Related]

  • 18. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D.
    Blood; 2011 Jan 27; 117(4):1270-9. PubMed ID: 21106982
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.